Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors
GlycoMimetics, Inc. (GLYC)
Last glycomimetics, inc. earnings: 5/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.glycomimetics.com/investor-relations
Company Research
Source: Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that it has appointed Scott Jackson, former Chief Executive Officer of Celator Pharmaceuticals, Inc., to its Board of Directors. Mr. Jackson served as Celator’s CEO and as a member of its Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. "As uproleselan advances in late-stage clinical trials in acute myeloid leukemia (AML), Scott’s experience leading Celator through the successful development of Vyxeos® for treatment of newly diagnosed AML patients will be invaluable to GlycoMimetics,” said Rachel King, GlycoMimetics’ Chief Executive Officer. “His deep operational experience, including in sales, marketing and commercialization, is directly relevant as we look forward to potentially commercializing this novel drug candidate.” Mr. Jackson has more th
Show less
Read more
Impact Snapshot
Event Time:
GLYC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLYC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLYC alerts
High impacting GlycoMimetics, Inc. news events
Weekly update
A roundup of the hottest topics
GLYC
News
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024Business Wire
- Loss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-Term [Yahoo! Finance]Yahoo! Finance
- GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- GlycoMimetics, Inc. (NASDAQ: GLYC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
GLYC
Earnings
- 3/27/24 - Beat
GLYC
Analyst Actions
- 3/27/24 - HC Wainwright
GLYC
Sec Filings
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- GLYC's page on the SEC website